TP53 and neoplasm: A series of intriguing questions, including whether identified mutant TP53 and CDKN2A tumor suppressor genes, respectively shared by CTCs and CECs, could function as a driver to promote those cells into circulation, whether aneuploid CECs in motion could provide a microenvironment for CTCs to facilitate metastatic lesion formation, and how aneuploid CTCs and CECs correlate with tumor formation and progression remains unclear.